Title: Pattern of Adverse Drug Reactions of Various Chemotherapeutic Agents in Cancer Patients in Kumaun Region
Authors: Gaur S, Sinha A.K, Gunjita B, Bhardwaj R, Renu K, Srivastava B.
DOI: http://dx.doi.org/10.18535/jmscr/v4i8.77
Abstract
Aim/Objective: To assess the ADRs due to cancer Chemotherapy in the tertiary care hospital in Kumoun region
Materials and Methods: It was a retrospective study conducted from ADR reporting form .The Study was conducted at the tertiary care centre at Dr. Sushila Tiwari Government Medical College Hospital & Swami Ram Cancer Institute Haldwani Nainital. The data was obtained from suspected ADRs reporting forms, between August 2015 to July 2016, from the Radiotherapy department to the ADRs monitoring centre attached to department of Pharmacology under the Pharmacovigilance programme of India (PvPi). The reported ADRs were assessed for causality using both WHO causality assessment scale and Naranjo’s algorithm. The severity was assessed using Hartwig and Siegel scale
Results: 187 ADRs were reported from 65 ADR Forms. Most common age group in which the patients had ADRs was 50-59 yrs36.92% followed by 50-59 yrs 23.07%. The most common cancer diagnosed were bronchogenic 21.53%, followed by carcinoma breast 18.46% and larynx 15.38% carcinoma cervix 7.69%, carcinoma nasopharyne and esophagus 6.15%. Most common occurring ADRs were nausea and vomiting 17.11%, headache 8.02%, Anxiety 6.95%, Dizziness 6.95%, Fever 5.88% and Elevated liver enzymes 3.20%. WHO causality scale indicated 59.89% of the reactions were “possible” and 40.10% “probable”. 62.56% were “moderate ” followed by “mild ” 34.75% and “severe”2.67% .Platinum compounds Cisplatin (40.00%) and Carboplatin (24.61%) followed by cyclophosphamide (7.69%) were the most frequent drugs causing ADRs
Conclusion: Cancer chemotherapeutic agents have a very high risk of ADR therefore there is a need for prompt detection of ADRs to decrease morbidity and mortality. Rational and judicious use of medicine and adapting preventive measures will reduce the burden of ADRs in the society and benefit mankind.
References
1. Lee A, Thomas SHL (2003) Adverse drug reactions. In: Clinical Pharmacy and Therapeutics Roger. (3rdedn), Churchill Livingstone, Spainp 33-34
2. World Health Organization. International Drug Monitoring: The Role of the Hospital. Geneva: World Health Organization; 1996.(Technical Report Services: No.425)
3. Beers MH, Berko R (1999) The Merck manual of Diagonosis and Therapy.(17thedn), Merck Publishing Group, USA.
4. White TJ, Arakelian A, Rho JP. Counting the costs of drug-related adverse events. Pharmacoeconomics. 1999;15(5):445-58.
5. Safety of Medicines-A Guide to Detecting and Reporting Adverse Drug Reactions-Why Health Professionals Need to Take Action [Internet]. Geneva: World Health Organization; c2002 [cited 2015 Oct2]. Available from: http://apps.who.int/iris/bitstream/10665/67378/1/WHO_EDM_QSM_2002.2.pdf
6. Sharma A, Kumari MK, Manohar HD, Bairy KL,Thomas J. Pattern of adverse drug reaction due to cancer chemotherapy in a tertiary care hospital in south india. Perspective in clinical research; 2015 6(2):109-115.
7. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239‑45.
8. Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 1992;49:2229‑32
9. Amartya De. Monitoring of suspected adverse drug reactions in oncology unit of an urban multispecialty teaching hospital, International Journal of Research in Pharmaceutical and Biomedical Sciences. 2010:1(2);1-32.
10. Soldin OP, Chung SH, Matison DR. Sex diferences in drug disposition. J Biomed Biotechnol 2011;2011:187103.
11. Gandhi M, Aweeka F, Greenblat RM, Blaschke TF. Sex diferences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol 2004;44:499‑523.
12. Poddar S, Sultana R, Sultana R, Akbor MM, Azad MA, Hasnat A. Patern of adverse drug reactions due to cancer chemotherapy in tertiary care teaching hospital in Bangladesh. Dhaka Univ J Pharm Sci 2009;8:11‑6.
13. Prasad A, Data PP, Bhatacharya J, Patanayak C, Chauhan AS, et al. Patern of adverse drug reactions due to cancer chemotherapy in a tertiary care teaching hospital in Eastern India. J Pharmacovigilance 2013;1:107.
14. Adithan C. National pharmacovigilance programme. Indian J Pharmacol 2005;37:347.
15. Hanlon JT, Ruby CM, Art M. Geriatrics. In: DiPiro JT, Talbert RL, Yee GC, Matke GR, Wells BG, Posey LM, editors. Pharmacotherapy A Pathophysiologic Approach. 5th ed. New York: McGraw Hill Inc.; 2002. p. 79‑89.
16. Surendiran A, Balamurugan N, Gunaseelan K, Akhtar S, Reddy KS, Adithan C. Adverse drug reaction profle of cisplatin-based chemotherapy regimen in a tertiary care hospital in India: An evaluative study. Indian J Pharmacol. 2010;42(1):40-3.
17. Mallik S, Palaian S, Ojha P, Mishra P. Patern of adverse drug reactions due to cancer chemotherapy in a tertiary care teaching hospital in Nepal. Pak J Pharm Sci 2007;20:214‑8.
18. Lau PM, Stewart K, Dooley M. The ten most common adverse drug reactions (ADRs) in oncology patients: Do they mater to you? Support Care Cancer 2004;12:626‑33.
19. Bellare PS , Ashwin k , PrakashPU K, Vinaykumar S , Rakesh KB. Aretrospective evaluation of adverse drug reactions due to cancer chemotherapy in a tertiary care hospital in south india. J Young Pharm,2016;8(3):251-254
20. Mittal N, Gupta MC. Comparison of agreement and rational uses of the WHO and Naranjo adverse event causality assessment tools. J Pharmacol Pharmacother. 2015;6(2):91-3
21. Macedo AF, Marques FB, Ribeiro CF, Teixeira F. Causality assessment of adverse drug reactions: comparison of the results obtained from published decisional algorithms and from the evaluations of an expert panel. Pharmacoepidemiol Drug Saf. 2005;14(12):885-90.
22. Blanc S, Leuenberger P, Berger JP, Brooke EM, Schelling JL. Judgments of trained observers on adverse drug reactions. Clin Pharmacol Ther. 1979;25(5):493-8.
23. Karch FE, Smith CL, Kerzner B, Mazzullo JM, Weintraub M, Lasagna L. Adverse drug reactions-a matter of opinion. Clin Pharmacol Ther. 1976;19(5 pt 1):489-92.